Diadema Partners LP Rhythm Pharmaceuticals, Inc. Transaction History
Diadema Partners LP
- $383 Billion
- Q1 2025
A detailed history of Diadema Partners LP transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 50,000 shares of RYTM stock, worth $3.1 Million. This represents 0.69% of its overall portfolio holdings.
Number of Shares
50,000
Previous 75,000
33.33%
Holding current value
$3.1 Million
Previous $4.2 Billion
36.92%
% of portfolio
0.69%
Previous 1.8%
Shares
2 transactions
Others Institutions Holding RYTM
# of Institutions
245Shares Held
62.9MCall Options Held
403KPut Options Held
62.8K-
Black Rock Inc. New York, NY6.74MShares$418 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$377 Million6.69% of portfolio
-
Primecap Management CO Pasadena, CA5.79MShares$359 Million0.26% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$347 Million3.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$213 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.45B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...